Previous close | 95.85 |
Open | 95.89 |
Bid | 25.96 x 800 |
Ask | 94.48 x 1000 |
Day's range | 94.18 - 96.17 |
52-week range | 71.83 - 103.00 |
Volume | 564,466 |
Avg. volume | 645,371 |
Market cap | 10B |
Beta (5Y Monthly) | 1.30 |
PE ratio (TTM) | 44.99 |
EPS (TTM) | 2.10 |
Earnings date | 29 Jan 2020 - 3 Feb 2020 |
Forward dividend & yield | 0.28 (0.29%) |
Ex-dividend date | 2020-01-16 |
1y target est | 95.85 |
PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that its GSP® Neonatal Creatine Kinase –MM (CK-MM) kit has received U.S. Food & Drug Administration (FDA) approval. This solution is the first commercially available assay for screening newborns affected by Duchenne muscular dystrophy (DMD).
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
PerkinElmer's (PKI) Q3 earnings benefits from higher revenues and growth in DAS and Diagnostics segments. However, forex remains a woe.
PerkinElmer (PKI) delivered earnings and revenue surprises of 4.95% and -2.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q3 earnings. However, forex is likely to have been a dampener.
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.
PerkinElmer, Inc. (NYSE:PKI), which is in the life sciences business, and is based in United States, saw significant...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Scientific Instruments Industry Outlook: Prospects Look Good
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Higher revenues and growth in Diagnostics segment benefit PerkinElmer's (PKI) Q2 earnings. However, forex remains a woe.
PKI earnings call for the period ending June 30, 2019.
PerkinElmer (PKI) delivered earnings and revenue surprises of -0.99% and -1.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
In this article we are going to estimate the intrinsic value of PerkinElmer, Inc. (NYSE:PKI) by taking the foreast...
Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.
Rob Friel has been the CEO of PerkinElmer, Inc. (NYSE:PKI) since 2008. This analysis aims first to contrast CEO...
PerkinElmer (PKI) raises earnings per share guidance for 2019.